VSTM
Verastem, Inc.
A biopharmaceutical company focused on fighting cancer, Verastem makes AVMAPKI FAKZYNJA CO-PACK (avutometinib/defactinib), a treatment for a rare form of ovarian cancer called low-grade serous ovarian cancer that received accelerated FDA approval in 2025. It's also developing VS-7375, an oral drug aimed at tumors driven by a common KRAS mutation. Based in the US, the company concentrates on the RAS/MAPK pathway, a key driver in many cancers.
CUSIP: 92337C104HealthcareUS1 holder
Total Value
$3.83M
Total Shares
9.22M
Net Share Change
0
Activity
No changes
Investor
Value
Shares
Weight
Change
